Foundation / Corporation
Lung Cancer Research Foundation (LCRF) and Pfizer Global Medical Grants (GMG)
Grants to USA postdoctoral investigators at nonprofit institutions for projects to improve the treatment of patients with lung cancer. A letter of intent must be submitted prior to submitting a full application. Funding is intended for innovative research projects that will significantly impact the management of side effects related to lung cancer therapies.
The Lung Cancer Research Foundation and Pfizer Global Medical Grants are collaborating to offer a new research grant opportunity focused on understanding ways to improve clinical practices for side effect management for non-small cell lung cancer (NSCLC) patients receiving targeted therapies. This collaborative funding mechanism is designed to support innovative health services research proposals that leverage multidisciplinary approaches to improve the management of targeted therapy toxicities.
Proposals on a variety of topics including the following are encouraged:
- Patterns of use and comparisons of real-world versus pre-approval patient experiences
- Defining and understanding tolerability (including late toxicities and patient-reported outcomes)
- Role of diverse, multi-disciplinary teams (including pharmacists, dieticians, caregivers, etc.) and coordination of care in managing and monitoring therapy
- Real-time symptom monitoring and implementation science approaches to improving care delivery
Approaches to management of toxicities in NSCLC patients treated with tyrosine kinase inhibitors, including but not limited to ALK, ROS1, and/or EGFR inhibitors, fall within the scope of this project.
Projects incorporating mixed-practice settings through collaborations such as in the NCI's Community Oncology Research Program, the SIMPRO Research Center, and other quality-of-care alliances are also encouraged.
In addition, the following costs are permitted:
- Overhead/indirect/F&A costs not exceeding 15% of the total*
- Publication expenses
GrantWatch ID#: 185892
The maximum award amount is $350,000.
Funding is for a period of two years.
All investigators at or above the level of postdoctoral fellow (or equivalent) who hold a tenure or non-tenure track faculty appointment at a US-based, non-profit academic or research institution are eligible to apply. Applicants from non-US institutions are not eligible to apply for this funding opportunity.
Not Permitted expenses:
- Direct patient care costs reimbursable by other sources
- Capital equipment
- Travel expenses
Approaches focused on side effects of immunotherapies are not eligible.
- RFP release date: April 29, 2019
- LOI deadline: June 24, 2019
- Full applications invited: August 1, 2019
- Application deadline: September 19, 2019
- Notification of award: November 12, 2019
- Project start: December 2019 / January 2020
Proposals for funding consideration must be submitted via a two-step process consisting of a letter of intent (LOI) followed by a full proposal. Upon submission and review of the LOIs, investigators whose proposals are deemed most relevant to the area of interest and demonstrate an exceptional level of scientific merit will be invited to submit full proposals.
Specific feedback will not be provided at the LOI stage. Summary feedback will be provided on full proposals.
All LOIs and subsequent full applications will be accepted via Pfizer’s online grants management system.
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
Apply online (Select the following Competitive Grant Program Name: LCRFManaging Side Effects of Targeted Therapies):
For questions, contact the LCRF office at firstname.lastname@example.org. You may also contact Jacqueline Waldrop, Grant Officer, Pfizer Inc. via email at Jacqueline.Waldrop@Pfizer.com.
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming